- Home
- HL vs ACLX Comparison
HL vs ACLX Comparison
Compare HL & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | ACLX |
|---|---|---|
| Founded | 1891 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 4.2B |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HL | ACLX |
|---|---|---|
| Price | $16.87 | $68.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $11.14 | ★ $115.50 |
| AVG Volume (30 Days) | ★ 16.9M | 1.2M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,224,563,000.00 | $35,898,000.00 |
| Revenue This Year | $43.45 | N/A |
| Revenue Next Year | $15.89 | $302.49 |
| P/E Ratio | $54.82 | ★ N/A |
| Revenue Growth | ★ 45.62 | N/A |
| 52 Week Low | $4.46 | $47.86 |
| 52 Week High | $18.12 | $94.07 |
Technical Indicators
Market Signals| Indicator | HL | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 65.70 | 33.01 |
| Support Level | $16.64 | $66.00 |
| Resistance Level | $18.12 | $75.03 |
| Average True Range (ATR) | 0.92 | 5.23 |
| MACD | 0.20 | -1.69 |
| Stochastic Oscillator | 78.00 | 12.96 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.